巴西研究所官宣：中國疫苗安全有效

China's Sinovac vaccine is safe, Brazil institute says

巴西研究所稱，中國的科興生物疫苗是安全的

BEIJING/SAO PAULO (Reuters) - An experimental coronavirus vaccine developed by China's Sinovac Biotech appeared to be safe in a late-stage clinical trial in Brazil, preliminary results showed on Monday.

路透北京/聖保羅 - 周一的初步結果顯示，中國科興生物科技公司研發的一種實驗性冠狀病毒疫苗在巴西進行的後期臨床試驗中似乎是安全的。

São Paulo's Butantan Institute, one of Brazil's leading biomedical research centers, which is carrying out the Phase 3 tests, said the two-dose vaccine, called CoronaVac, proved to be safe in a trial so far involving 9,000 volunteers.

聖保羅的布坦坦研究所是巴西領先的生物醫學研究中心之一，正在進行第三階段測試。該研究所表示，到目前為止，在一項涉及9000名志願者的試驗中，這種名為CoronaVac的兩劑疫苗被證明是安全的。

But Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed on all of the 13,000 volunteers.

但布坦坦主任迪馬斯·科瓦斯表示，在對所有1.3萬名志願者完成試驗之前，不會公布疫苗有效性的數據。

"The first results of the clinical study conducted in Brazil prove that among all the vaccines tested in the country, CoronaVac is the safest, the one with the best and most promising rates," São Paulo Governor João Doria told reporters.

聖保羅州長約翰·多裡亞告訴記者：「在巴西進行的臨床研究的第一批結果證明，在該國測試的所有疫苗中，CoronaVac是最安全的，也是效率最好、最有希望的一種。」

The result is only preliminary and researchers will keep monitoring the participants in the on-going trial, Covas said. It's the first set of results of Sinovac's Phase 3 global trials, which are also being conducted in Turkey and Indonesia.

科瓦斯說，結果只是初步的，研究人員將繼續監測正在進行的試驗中的參與者。這是科興生物第三階段全球試驗的第一組結果，該試驗也在土耳其和印度尼西亞進行。

Covas said there were no severe adverse reactions to the vaccine, with 20% of the volunteers reporting mild pain from the injection while 15% reported headaches after the first dose, dropping to 10% for the second. Less than 5% reported nausea or tiredness, and even less had muscle aches, he said.

科瓦斯說，疫苗沒有出現嚴重的不良反應，20%的志願者報告注射後有輕微疼痛，而15%的志願者報告在第一次注射後頭痛，第二次注射後下降到10%。他說，只有不到5%的人報告有噁心或疲倦，甚至更少的人有肌肉疼痛。

São Paulo state health secretary Jean Gorinchteyn said the vaccine appeared to produce protective anti-bodies. The state hopes to obtain regulatory approval for CoronaVac by the end of the year to start inoculating its population early in 2021, in what could the first vaccination programs in the Americas.

聖保羅州衛生部長讓·戈林奇廷表示，疫苗似乎能產生保護性抗體。該州希望在今年年底前獲得監管部門對CoronaVac的批准，在2021年初開始為其人口接種疫苗，這可能是美洲第一個疫苗接種計劃。

São Paulo signed a deal with Sinovac to buy 60 million doses by the end of February.

聖保羅與科興生物籤署了一項協議，在2月底之前購買6000萬劑。

Sinovac wanted Brazil as a testing ground because it has been one of the global hotbeds of the virus, although cases are 43% off their peak of nearly 70,000 new cases a day in late July.

科興生物希望巴西作為試驗場，因為它一直是該病毒的全球溫床之一，儘管病例比7月下旬每天近7萬例的峰值下降了43%。

Brazil has reported more than 5.2 million COVID-19 cases since the pandemic began, the world's third most-affected country after the United States and India.

自疫情開始以來，巴西已經報告了520多萬例新冠肺炎病例，是僅次於美國和印度的世界第三大受影響國家。

AstraZeneca PLC and Oxford University are nearing an analysis of their UK coronavirus vaccine trial. Pfizer Inc has said it could provide an early analysis of its trial this month, and Moderna Inc may announce its results in November. Russia's Gamaleya Institute may provide an analysis of its vaccine in the next month.

阿斯利康和牛津大學即將對他們的英國冠狀病毒疫苗試驗進行分析。輝瑞公司表示，本月可能會提供試驗的早期分析，現代公司可能會在11月公布結果。俄羅斯的加馬列亞研究所可能在下個月提供其疫苗的分析報告。

Competing candidates developed by AstraZeneca and Johnson & Johnson have had their trials halted in the United States due to safety issues.

由阿斯利康和強生公司開發的競爭對手因安全問題在美國暫停了試驗。

Vaccines are considered as essential tools to curb the rampaging virus, which has killed over 1 million people globally. Brazil is also hosting a Phase 3 trial for AstraZeneca's vaccine candidate, while Johnson & Johnson said last month it aims to expand its final-stage human trials there.

疫苗被認為是遏制肆虐的病毒的必要工具，這種病毒已導致全球100多萬人死亡。巴西還主辦了阿斯利康候選疫苗的第三階段試驗，而強生公司上個月表示，它的目標是擴大在那裡的最後階段人體試驗。

CoronaVac uses inactivated vaccine technology, a traditional method that uses killed virus that cannot replicate in human cells to trigger an immune response.

CoronaVac使用滅活疫苗技術，這是一種傳統的方法，使用無法在人類細胞中複製的被殺病毒來觸發免疫反應。

Experts have warned that the safety of inactivated coronavirus vaccine candidates should be observed over longer periods, as some other inactivated vaccines had led to disease enhancement effect, where vaccine-triggered antibodies, instead of offering protection, could worsen infections when people became exposed to a virus after inoculation.

專家警告說，應該在更長的時間內觀察滅活冠狀病毒候選疫苗的安全性，因為其他一些滅活疫苗已經導致了疾病增強效應，當人們在接種疫苗後接觸到病毒時，疫苗引發的抗體非但不能提供保護，而且可能會加劇感染。